On March 17, 2026, BioCardia, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter. This device is intended for the intramyocardial delivery of therapeutic and diagnostic agents, a significant advancement in the treatment of cardiovascular diseases. The acceptance of this package is a crucial step towards obtaining FDA marketing clearance, which BioCardia's CEO, Peter Altman, Ph.D., emphasized as vital for the company's business and the broader field of cardiac cell therapies. The Helix catheter is designed to enable precise delivery of agents within the heart, enhancing retention and access to areas that other delivery methods cannot reach. The FDA's acknowledgment of the CardiAMP Cell Therapy Breakthrough Designation, enabled by Helix, is expected to facilitate the approval process for BioCardia's CardiAMP Cell Therapy aimed at treating ischemic heart failure. This development is anticipated to have a noticeable positive effect on BioCardia's stock price as it progresses towards potential commercialization and further clinical advancements.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.